REGENERON PHARMACEUTICALS, INC.
An institutional investment manager in TARRYTOWN, NY. Its Form 13F for the quarter ended Jun 30, 2026, filed Aug 7, 2026. SEC CIK 872589.
- Reported value$177.2m
- Positions3
Holdings: 3 positions
The filing on sec.govAs filed, largest first. Reported value is what the manager stated for each position at the quarter end, in US dollars; it is filing data, not a price. Weight is the position's share of the total reported value. Changes compare with the 13F for the quarter ended 2026-03-31.
| Issuer | Class | CUSIP | Reported value$m | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Parabilis Medicines, Inc.PBLS | Common Stock | 698955101 | 114 | 64.4% | 4,166,666 | New+4,166,666 | |
| Intellia Therapeutics, Inc.NTLA | Common Stock | 45826J105 | 62.7 | 35.4% | 3,702,995 | Unchanged | |
| Adicet Bio, Inc.ACET | Common Stock | 007002207 | 0.5 | 0.3% | 60,511 | New+60,511 |
Sold out: 1 position
Held at the end of the quarter before and not reported this quarter.
| Issuer | Class | CUSIP | Reported value$ | Weight | Shares | Put or call | Change on the quarter before |
|---|---|---|---|---|---|---|---|
| Adicet Bio, Inc. | Common Stock | 007002108 | 0.0 | 0.0% | 0 | Sold out−60,511 |
Source: SEC EDGAR, Form 13F-HR, accession 0001104659-26-092709 (on sec.gov). Last ingested by Listed: Oct 22, 2026, 05:26 ET. Listed shows no prices and gives no investment advice.